Æterna Zentaris, Inc. (AEZS) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

3.4 k

Shareholding (Mar 2025)

FII

0.87%

Held by 25 FIIs

DII

99.13%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

The company has declared Negative results for the last 4 consecutive quarters

OPERATING CASH FLOW(Y) Lowest at CAD -23.73 MM
NET PROFIT(HY) At CAD -8.48 MM has Grown at -35.93%
INTEREST(HY) At CAD 0.13 MM has Grown at 14.95%

Risky - No result in last 6 months

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 13 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.29

Return on Equity

-216.92%

Price to Book

1.33

Revenue and Profits:

Net Sales:

4 Million

(Quarterly Results - Jun 2025)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

571.33%

6 Months

260.45%

1 Year

198.48%

2 Years

29.15%

3 Years

51.18%

4 Years

-17.71%

5 Years

-54.43%

Æterna Zentaris, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

46.33%

EBIT Growth (5y)

-163.00%

EBIT to Interest (avg)

-14.62

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.33

Sales to Capital Employed (avg)

0.42

Tax Ratio

3.00%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

1.33%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.11

EV to EBIT

0.08

EV to EBITDA

0.09

EV to Capital Employed

0.61

EV to Sales

-0.13

PEG Ratio

Dividend Yield

ROCE (Latest)

726.29%

ROE (Latest)

-216.92%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 25 Foreign Institutions (0.87%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 72.73% vs -52.17% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 28.85% vs 44.68% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.80",
          "val2": "2.20",
          "chgp": "72.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.90",
          "val2": "-4.70",
          "chgp": "38.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.70",
          "val2": "-5.20",
          "chgp": "28.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-855.90%",
          "val2": "-2,411.30%",
          "chgp": "155.54%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 36.46% vs 31.51% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -346.81% vs 84.12% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "13.10",
          "val2": "9.60",
          "chgp": "36.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-17.00",
          "val2": "-4.30",
          "chgp": "-295.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.00",
          "val2": "-4.70",
          "chgp": "-346.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,462.70%",
          "val2": "-648.00%",
          "chgp": "-81.47%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

3.80

2.20

72.73%

Operating Profit (PBDIT) excl Other Income

-2.90

-4.70

38.30%

Interest

0.00

0.10

-100.00%

Exceptional Items

-0.50

-0.00

Consolidate Net Profit

-3.70

-5.20

28.85%

Operating Profit Margin (Excl OI)

-855.90%

-2,411.30%

155.54%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 72.73% vs -52.17% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 28.85% vs 44.68% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

13.10

9.60

36.46%

Operating Profit (PBDIT) excl Other Income

-17.00

-4.30

-295.35%

Interest

0.20

Exceptional Items

-2.30

0.00

Consolidate Net Profit

-21.00

-4.70

-346.81%

Operating Profit Margin (Excl OI)

-1,462.70%

-648.00%

-81.47%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 36.46% vs 31.51% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -346.81% vs 84.12% in Dec 2023

All Annual Results

Company CV

About Æterna Zentaris, Inc.

Æterna Zentaris, Inc.

Pharmaceuticals & Biotechnology

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Company Coordinates

Company Details

41st, 1155 Rene-Levesque Blvd W Flr 4000 , MONTREAL QC : H3B 3V2

Tel: 1 843 9003223

http://www.aezsinc.com/

Registrar Details